Skip to search formSkip to main contentSkip to account menu

ICRF-187

Known as: ICRF 187, ICRF187 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

DexrazoxaneDexrazoxane hydrochloride
Zinecard

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
Pharmacokinetics of etoposide in cancer patients treated with high-dose etoposide and with dexrazoxane (ICRF-187) as a rescue agent
Purpose: The pharmacokinetics of etoposide were studied in cancer patients with brain metastases treated with high-dose etoposide… 
2006
2006
Novel Topoisomerase II Catalytic Inhibitor That Induces S-Phase Retardation and Mitotic Delay in Human Hepatoma HepG 2 Cells
Epidemiological evidence suggests that high consumption of Brassica genus vegetables, such as broccoli, cabbage, and Brussels… 
2003
2003
The G 2-phase Decatenation Checkpoint Is Defective in Werner Syndrome Cells 1 , 2
It has been proposed that cells monitor chromatid catenation status after DNA replication and inhibit progression into mitosis… 
2000
2000
Characterization of the biological and biochemical activities of F 11782 and the bisdioxopiperazines, ICRF-187 and ICRF-193, two types of topoisomerase II catalytic inhibitors with distinctive…
F 11782 is a newly identified catalytic inhibitor of topoisomerases I and II, without any detectable interaction with DNA. This… 
1993
1993
[Prevention of cardiotoxicity of doxorubicin (Adriamycin) using cardioxane (ICRF-187, dexrazoxane) in the combination chemotherapy of disseminated breast cancer].
Clinical, ultrasound and ECG studies of the left ventricle ejection fraction (LVEF) carried out in 25 patients with extensive… 
1993
1993
[Prevention of cardiotoxicity of doxorubicin (Adriamycin) using cardioxane (ICRF-187, dexrazoxane) in the combination chemotherapy of disseminated breast cancer].
: Clinical, ultrasound and ECG studies of the left ventricle ejection fraction (LVEF) carried out in 25 patients with extensive… 
Review
1991
Review
1991
ICRF-187 (ADR-529) cardioprotection against anthracycline-induced cardiotoxicity: clinical and preclinical studies.
Anthracyclines are anticancer agents that are effective in a wide range of tumors. Unfortunately, their activity is limited by… 
1988
1988
A Trial of ICRF-187 to Selectively Protect Against Chronic Adriamycin Cardiac Toxicity: Rationale and Preliminary Results of a Clinical Trial
The wide spectrum of anthracycline activity as well as the unique cumulative dose related cardiac toxicity pose a significant… 
1988
1988
Pretreatment with ICRF-187 Protects Against the Chronic Cardiac Toxicity Produced by Very Large Cumulative Doses of Doxorubicin in Beagle Dogs
The optimal use of anthracyclines, such as doxorubicin and daunoruoicin, in cancer chemotherapy is hampered by the serious… 
1987
1987
Rationale and strategy for prevention of anthracycline cardiotoxicity with the bisdioxopiperazine, ICRF-187.
Anthracyclines are amongst the most effective antitumor agents currently utilized. The major impediment to their use has been the…